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A B S T R A C T
The aim of the study was to evaluate the natural course and potential risk factors of autoimmune thyroiditis (AIT)
and thyroid dysfunction, and their influences on growth and glycemic control in children and adolescents with type 1 di-
abetes mellitus (T1D). The study comprised 148 subjects (age range 1–21 years; males 51%) with T1D. During the inter-
val of 12 years serum levels of thyroid peroxidase (anti-TPO) and thyroglobulin (anti-TG) autoantibodies, thyroid-stimu-
lating hormone (TSH) and tyroksine (T4), were screened annually. Height, weight, body mass index (BMI), glycosylated
hemoglobin (HbA1c), insulin dose and the number of severe hypoglycemic episodes, were recorded every 3 months.The
mean folow-up was 7 ± 4.1 years. Prevalence of AIT in subjects with T1D was 15.5%. It was significantly higher in girls
(21.9% vs. 9.3%; p=0.03). The mean age at AIT onset was 11.5 ± 5.2 years. The mean interval between negative and posi-
tive AIT screening was 2.5 ± 2.3 years. Cumulative incidence of AIT after 6 years of T1D duration was significantly
higher in girls (30% vs. 15%; p=0.03). Prevalence of hypothyroidism was 8.1% with no significant differences in sex dis-
tribution. Prevalence of hypothyroidism among subjects with elevated serum thyroid antibodies was 52.2% with signifi-
cant male preponderance (85.7% vs. 37.5%; p=0.005). There were no subjects who developed hypothyroidism in absence
of thyroid antibodies. Cumulative incidence of hypothyroidism after 3 years from the moment of thyroid antibodies ap-
pearance was 55% with significant male preponderance (85% vs. 40%; p=0.005). The mean interval between T1D onset
and hypothyroidism development was 3.3 ± 2.5 years, and between thyroid antibodies appearance and hypothyreoidism
development was 1.7 ± 1.2 years. The mean age at hypothyroidism onset was 12.7 ± 5.3 years. There were no differences
in growth and metabolic control between patients with and without AIT. The results of the present study confirmed fre-
quent occurrence of AIT and thyroid dysfunction in subjects with T1D. The number of newly diagnosed subjects with
AIT reached the peak at the age of puberty. Girls were significantly more predisposed to AIT at any age while amongst
subjects with elevated thyroid antibodies boys developed hypothyroidism more frequently. Annual screening of thyroid
antibodies in all patients with T1D is recommended, while serum TSH level should be measured in patients with de-
tected thyroid antibodies.
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Introduction
Type 1 diabetes mellitus (T1D) is often associated
with the presence of other autoimmune diseases.
Amongst them, autoimmune thyroiditis (AIT) has the
most frequent occurence1,2. Elevated serum level of anti-
bodies against thyroperoxidase (anti-TPO) and thyro-
globulin (anti-TG) is a distinctive abnormality that per-
mits a presumptive diagnosis of AIT3. AIT is often clini-
cally silent but it may progress to autoimmune thyroid
disease (AITD) characterized by either overt or sub-
clinical presentation of hypothyroidism or hyperthyroi-
dism4–6. The reported prevalence rates of AIT in children
and adolescents with T1D vary from 3,9 to 50%7–12.
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These results are in contrast to low AIT prevalence of
3,4–4,5% found in general population13,14.
A detailed understanding of natural course of AIT as-
sociated with T1D is still lacking and there are many
questions to be answered about it: Which of the diseases
precedes in the course, T1D or AIT? What proportion of
the patients with T1D have elevated serum level of thy-
roid antibodies, and how many of them will develop thy-
roid disfunction? When do these events occure in course
of T1D?
Furthermore, the role of possible risk factors, such as
patient’s age and sex, duration of T1D and presence of
thyroid antibodies, for development of AIT and thyroid
disfunction in children and adolescents with T1D has to
be elucidated too.
Due to a small number of performed studies there has
been little insight into the epidemiological aspects and
natural course of AIT associated with T1D. Therefore,
existing recommendations considering diagnostic detec-
tion of AIT and thyroid disfunction in patients with T1D
vary remarkably.
According to the International Society for Pediatric
and Adolescent Diabetes (ISPAD) investigation of thy-
roid function and detection of thyroid antibodies should
be performed at the onset of diabetes, and should be re-
peated only in case of emerging symptoms suggesting
thyroid disfunction15. Thus, screening of asymptomatic
patients is not recommended by ISPAD.
On the other hand, American Diabetes Association
(ADA) recommends TSH screening at the onset of diabe-
tes and following its stabilisation. TSH screening should
also be performed later if symptoms of hypo or hyper-
thyroidism are suspected. In case of confirmed hypo or
hyperthyroidism screening should be repeated once a
year or every two years1. According to ADA neither
screening of thyroid antibodies nor screening of thyroid
function in clinically euthyroid patients with positive an-
tibodies are recommended.
Furthermore, there are conflicting reports on possible
influence of AIT upon growth and development, and
metabolic control in diabetic patients. Some results sho-
wed that thyroid dysfunction has no influence on BMI,
lipidemia and HbA1c4,16,17, whereas there are opposite re-
ports showing a significant impairment of glycemia cau-
sed by thyroid dysfunction1. Hyperthyroidism can result
in a sudden increase of HbA1c18, and hypothyroidism,
even if subclinical, can be associated with significant risk
for the development of symptomatic hypoglicemia19,
growth delay20, weight gain, menstrual abnormalities,
and poor condition in general21. Moreover, hypothyroi-
dism can lead to hyperlipidemia and its cardiovascular
complications which have more frequent occurence in di-
abetic patients anyway22,23. In order to prevent all these
complications early diagnosis of AIT and thyroid dys-
function is esential.
The aim of this study was to evaluate some epidemio-
logical and clinical aspects of AIT and thyroid dysfunc-
tion, includnig potential risk factors for their onset, in
children and adolescents with T1D. Their influence on
growth and glycemic control in diabetic patients was also
analysed. After all, recommendations considering an effi-
cient screening of AIT in children and adolescents with
T1D were provided.
Patients and Methods
The study comprised 148 children and adolescents
suffering from T1D. Their age ranged 1–21 years, and
they showed an equal sex distribution (75 males; 50.7 %).
Their mean age at the time of T1D diagnosis was 9.5 (±
4.2) years with the range of 1.3–17.9 years. All the pa-
tients included in the study were diagnosed and managed
at the Paediatric Clinic, Clinical Hospital Center Rijeka,
between Jannuary 1995. and Jannuary 2005. Their
mean follow up was 7.0 ± 4.1 years. The diabetic patients
were regularly screened for AIT and thyroid dysfunction
once a year, and according to the results they were di-
vided in two groups: the group with and the group with-
out associated AIT.
Diagnostic detection of AIT was performed by mea-
suring anti-TG and anti-TPO concentrations in serum
using chemiluminescent sequential immunometric assay
IMMULITE Anti-TG Ab and Anti-TPO Ab, DPC, Los An-
geles, USA. The reference values were: <40 IU/mL for
anti-TG, and <35 IU/mL for anti-TPO. The serum levels
of thyroid antibodies >100 IU/mL were considered to be
significantly increased. Thyroid function was determi-
ned by measurement of serum TSH and T4 using im-
munoradiometric assay BRAHMS, Hennigsdorf, Germa-
ny. The reference values were: 0.3–5.0 mIU/L for TSH,
and 58–154 nmol/L for T4. In case of thyroid dysfunction
and/or presence of thyroid antibodies ultrasonography
was performed because the finding of hypoechogeneous
and inhomogeneous structure of usually enlarged thy-
roid gland is typical for AIT16.
Patients with T1D underwent regular examinations,
at least every three months, which included measure-
ments of hight and weight, and calculation of BMI. The
z-score for height and BMI was calculated based on the
Zurich longitudinal growth data24. In addition, insulin
dose (U/kg), number of severe hypoglycemic episodes
(events/diabetes year) and glycosylated hemoglobin
(HbA1c), were recorded. Measurement of HbA1c was
performed using chromatographic spectrophotometry by
Byo Systems, Barcelona, Spain, with the reference range
of 4–6 % for non-diabetics.
Statystical analysis was performed using MedCalc
Software, Mariakerke, Belgium, and Statistica, StatSoft,
USA. Group comparisons were performed using t-test,
c2-test, and Man-Whitney U-test. Data are presented as
mean ± SD for normally distributed variables or as me-
dian and range for nongaussian distributed parameters.
Kaplan-Meier analysis was used to calculate and to com-
pare cumulative incidence among the study groups. Sig-
nificant differences were assumed at a value of p<0.05.
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Results
Calculated prevalence rate of AIT in children and ado-
lescents suffering from T1D was 15.5% (23 of 148). The
female/male ratio was 2.3:1 suggesting significantly (p=
0.03) more frequent occurence of AIT in female (16 of 73;
21.9%) than in male (7 of 75; 9.3%) patients.
Anti-TPO and anti-TG were detected in 21 (14.2%)
and 17 (11.5%) patients respectively. The mean age of
AIT onset was 11.5 ± 5.2 years, ranging 1.5–18.5 years.
The mean interval between negative and positive results
of AIT screening was 2.5 ± 2.3 years, ranging 0–6.1 years.
There were 8 patients with AIT at initial screening
and 15 patients developed AIT in the course of the next
six years. Afterwards, there were no newly diagnosed di-
abetic patients with AIT (Figure 1).
Cumulative incidence rate of AIT in all patients after
six years of diabetes duration was 22% (Figure 2A). It
was significantly (p=0.0254; hazard ratio 0.3823; 95% CI
0.169 to 0.89) higher in female (30%) than in male (15%)
patients (Figure 2B).
There was no significant difference (p=0.91) of the
mean age of T1D onset between patients with (10 ± 4.9
years) and without (9.9 ± 4.2) associated AIT.
The apparition of AIT became more frequent as pa-
tients became older. The peak of AIT occurence fell into
the age group 11–15 years (p=0.03) (Figure 3).
Hypothyroidism was present in 12 (8.1%) of all 148 di-
abetic patients. There were 6 male (8.0% of all male dia-
betics) and 6 female (8.2% of all female diabetics). There
were any patients with hyperthyroidism.
Hypothyroidism developed in 12 of 23 (52.2%) pa-
tients with positive finding of thyroid antibodies. There
were no diabetic patients with hypothyroidism and si-
multaneously being negative for thyroid antibodies.
The mean interval between T1D onset and develop-
ment of hypothyroidism was 3.3 ± 2.5 years. The mean
interval between appearance of thyroid antibodies and
development of hypothyrodism was 1.7 ± 1.2 years. Hy-
pothyroidism developed at the mean age of 12.7 ± 5.3
years, ranging 1.5–19.3 years.
Among the diabetic patients with positive finding of
thyroid antibodies hypothyroidism showed significantly
more (p<0.01) frequent occurrence in males. In other
words, 6 of 7 (85.7%) male patients with positive finding
of thyroid antibodies, in analogous comparison to only 6
of 16 (37.5%) female patients, developed hypothyroidism.
There is no significant difference (p=0.34) in the
mean age of T1D onset between the patients with and
without hypothyroidism. The patients with positive find-
ing of thyroid antibodies were followed up for 8.0 ± 3.6
years. The mean age of T1D onset in those who remained
euthyroid was 11.9 ± 5.0 years in comparison to the mean
age of 8.45 ± 5.8 years of patients who developed hypo-
thyroidism.
Cumulative incidence rate of hypothyroidism in all di-
abetic patients, 3.5 years following the moment of thy-
roid antibodies detection, was 55 %. Afterwards, there
were no newly diagnosed patients with hypothyroidism
(Figure 4A).













































Fig. 1. The number of newly diagnosed patients with autoimmu-
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Fig. 2. Kaplan Meier curve shows probability of autoimmune thy-
roiditis (AIT) onset, or cumulative incidence(CI) in relation to
the duration of type 1 diabetes in all patients (A), and according
























Fig. 3. The number of diabetic patients with autoimmune thyroi-


















































Interval between the moment of TAB
detection and development of HT (years)
Interval between the moment of TAB
detection and development of HT (years)
Fig. 4. Kaplan Meier curve shows probability, or cumulative inci-
dence (CI) of hypothyroidism (HT) in relation to elevated antithy-
roid antibodies(TAB) in all diabetic patients (A), and according
to the gender(B). Thus, these are intervals between the moment of
TAB detection and development of HT.
Cumulative incidence rate of hypothyroidism was sig-
nificantly (p<0.01; hazard ratio 3.8386; 95% CI 1.939 to
43.5512) higher in male (85 %) than in female (40 %) pa-
tients. At the initial screening the cumulative incidence
rate was 57 % in males, in comparison to only 6 % in fe-
males. Cumulative incidence showed an increased ten-
dency in females reaching the rate of 40 % three years
later. On the other hand, cumulative incidence of hypo-
thyroidism in males reached the peak 2.5 years following
the moment of thyroid antibodies detection (Figure 4B).
There were 2 patients with hypothyroidism at initial
screening of thyroid antibodies, and 10 patients devel-
oped hypothyroidism in the course of the next four years.
Afterwards, there were no newly diagnosed diabetic pa-
tients with hypothyroidism (Figure 5).
There was an increasing trend of the number of newly
diagnosed diabetic patients with hypothyroidism showed
an increasing trend as they became older, but not in a sig-
nificant manner (p=0.34) (Figure 6).
Anti-TG were negative in 5 of 12 patients with hypo-
thyroidism in comparison to anti-TPO which were de-
tected in 11 of 12 patients with thyroid dysfunction.
Thus, anti-TG showed less sensitivity (58%) than anti-
-TPO which could predict the development of thyroid
dysfunction with 92 % of sensitivity.
There was no significant difference (p=0.06) in thy-
roid function between the patients with low (100–1000
IU/mL) and high (>1000 IU/mL) serum level of thyroid
antibodies.
Ultrasonographic finding of thyroid gland was abnor-
mal in majority of diabetic patients with AIT (n=21/23).
However, there was no significant difference (p=0.054)
between hypothyroid and euthyroid patients with AIT.
There is no significant difference in height, in BMI, in
insuline dose and in the number of severe hypoglycemic
episodes between the diabetic patients with or without
associated AIT (Table 1).
Discussion
The results of this study showed that the prevalence
of AIT and AITD is higher among children and adoles-
cents suffering from T1D than in general popula-
tion13,14,25. This is in accordance with results of many
similar studies with reported prevalence rates of AIT in
diabetic patients varying from 15 to 20%9,16,26–28.
The lowest prevalence rate of AIT in diabetic children
of 3.9% was reported by authors from Italy, Austria and
Croatia more than a decade ago. This was an interna-
tional multicentric study which included investigators of
the present study too. At that period the reported preva-
lence rate of AIT in Croatian diabetic children was
11.8%7. The very highest prevalence of AIT in diabetic
patients was reported by Burek. He found the prevalence
rate of detected thyroid antibodies to be even 50% among
caucasian children and adolescents suffering from T1D
in USA12. The reason for such expressive variations of


































Interval between thyroid antibodies detection
and development of hypothyroidism (years)
Fig. 5. The number of newly diagnosed diabetic patinets with hy-
pothyroidism in relation to presence of thyroid antibodies.
TABLE 1
CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PATIENTS WITH TYPE 1 DIABETES WITHOUT AND WITH AUTOIMMUNE
THYROIDITIS
Patients with T1D without AIT
N=125; X ± SD
Patients with T1D and AIT
N=23; X ± SD
p
Height SD score 0.47 ± 0.9 0.14 ± 0.9 0.16
BMI SD score 0.1 ± 0.7 0.11 ± 0.8 0.73
Insulin dose (units/kg/day) 0.7 ± 0.4 0.8 ± 0.3 0.39
HbA1c (%) 8.1 ± 1.7 8.5 ± 0.5 0.12
Severe hypoglycemias
(events/diabetes year)
0.3 ± 0.36 0.4 ± 0.34 0.33

























Fig. 6. The age at onset of hypothyroidism in diabetic patients
wit autoimmune thyroiditis.
AIT prevalence in diabetics could probably be explained
by genetic factors along with a lack of methodological
uniformity concerning thyroid antibodies detection. The
lower prevalence rates reported in earlier studies could
have been a consequence of available less sensitive diag-
nostic tests though there might be a real increase of AIT
incidence over the last few decades.
In the majority of published studies female sex was
emphasized as one of the most important risk factors for
development of AIT and thyroid dysfunction in diabetic
patients. The usual reported female/male ratio seems to
be 2–3:19,27,29,30, but there are some studies which did not
find significant sex distribution among diabetic patients
with associated AIT4,16,26. The present study confirmed
significantly more frequent occurrence of AIT in female
diabetics while the prevalence of hypothyroidism was
equally distributed between sexes. However, in the group
of patients with positive thyroid antibodies hypothyroi-
dism developed more frequently in male patients. This
result is in contrast to existed published data which
showed female preponderance in this group of patients.
Even in general population of children and adolescents
with the reported prevalence of thyroid antibodies of
3.4%, there is a female preponderance with female/male
ratio 2.7:113. More frequent occurrence of AIT in females
is attributed to hormone influences31.
Thyroid antibodies are indicators of the presence of
AIT which is usually asymptomatic, but it can evolve to
subclinical or manifest, hypo or hyperthyroidism4,5,32.
There is a question about dynamism of thyroid anti-
bodies apparition and development of thyroid dysfunc-
tion. Are these events under the influence of patient’s
sex and age, or they are affected by duration of T1D?
According to research data hypothyroidism evolve in
4–68 % of patients with T1D, but only in 5–10% of sub-
jects in general population. It has a higher prevalence in
older people and in women in both groups4,5,7,11,26–30,33–37.
The present study showed that thyroid antibodies
were detected in the majority of patients at the inital
screening. This is in accordance with many studies re-
porting a high proportion of diabetic patients with AIT
who were detected at the very beginning of T1D. Gonza-
les detected anti-TPO in 14.2% of patients at the begin-
ning of T1D, and reported on 68% of patients who devel-
oped hypothyroidism subsequently30. According to Fran-
zese 55% of patients had elevated serum levels of thyroid
antibodies at the initial screening. In others thyroid anti-
bodies were detected after the mean interval of T1D du-
ration of 7 years. Hypothyroidism evolved in 14,3% of pa-
tients with AIT27. Umiperez has also reported that in the
majority of patients thyroid antibodies were detected at
the beginning of the study, and only one patient became
positive 12 years later4. The incidence rate of AITD of
0.91 on 100 patient’s years was reported by Glastras11.
Progresion to hypothyroidism in patients with positive
thyroid antibodies occurs in 5–7%/year and in 20–24%/
year in elderly patients38,39.
The mean interval between negative and positive re-
sults of thyroid antibodies was similar to the mean inter-
val of 2.8 years stated in literature data11. The calculated
values of the mean intervals between T1D onset and de-
velopment of hypothyroidism, between thyroid antibod-
ies detection and development of hypothyroidism, and
the median age of hypothyroidism onset, have also sho-
wed a good correspondance when comparing the results
of the present study and literature data5,9.
Investigators that included T1D patients of all ages,
reported somewhat longer period of time needed for
hypothyroidism development4,30.
There are seldom studies in children that included
calculation of cumulative incidence or probability of AIT
appearance. One of such studies showed that cumulative
incidence of AIT at the age of 18 years was 14% in all sub-
jects suffering from T1D, with a significant female pre-
dominance. Cumulative incidence of AIT after 10 years
of T1D duration was 14%, and its rate again was signifi-
cantly higher in girls9.
In the present study the peak of AIT cumulative inci-
dence was reached after 6 years of T1D duration with
significantly higher rate in girls. During the next 6-year
period of follow-up there were no newly diagnosed pa-
tients with AIT. Girls were more predisposed to AIT at
any age.
In the study conducted by Kordonouri subjects were
attended for 15 years of T1D duration. The peak of AIT
cumulative incidence was reached by boys after 10 years
of T1D duration in comparison to 13 years in girls9.
In the present study, the interval between appearance
of thyroid antibodies and hypothyroidism was repre-
sented as cumulative incidence. Its peak was reached 3.5
years following the appearance of thyroid antibodies. Cu-
mulative incidence of hypothyroidism was significantly
higher in boys than in girls. At the initial screening the
cumulative incidence rate in boys exceeded by far the one
in girls. However, the latter rate increased subsequently
reaching its peak 3.5 years later. The peak of hypo-
thyroidism cumulative incidence was reached in boys 2.5
years following the appearance of thyroid antiboides. Al-
though the follow-up of subjects continued for ten years
it is interesting to notice that after 3.5 years from the
moment of thyroid antibodies detection there were no
newly registered cases with hypothyroidism.
Since the literature data are in contradiction, there is
a question concerning the age at onset of T1D as a possi-
ble risk factor for more expeditious evolution of AIT and
AITD. The results of the present study showed no signifi-
cant differences of subjects age at T1D onset between the
patients with and without AIT, as well as between the pa-
tients with or without thyroid dysfunction. These results
are in accordance with many published reports5,11. On
the other hand, there are authors with different conclu-
sions suggesting that AIT prevalence decreases along
with the increasing age at T1D onset40, or that the age at
T1D onset was significantly higher in the group of dia-
betic patients with an early appearance of AIT in com-
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parison to the patients who developed AIT later, or to the
diabetic patients who did not develop AIT at all27. Gonza-
les reported that the diabetic patients who developed
hypothyroidism had met with the onset of T1D at their
older age30.
Many investigators found by far more frequent occu-
rence of hypothyroidism in diabetic patients in the pres-
ence of thyroid antibodies4,9,11,30,. There were any pa-
tients in the present study that developed hypothyroi-
dism in the absence of thyroid antibodies. It is worth to
remark that, in addition to the obligatory iodine supple-
mentation of salt, Croatia is not an iodine-deficient area.
In accordance with many other reports30,41,42 there
was greater proportion of detected anti-TPO than anti-
TG in presented diabetic patients with AIT. Furthemore,
anti-TG showed to be less sensitive marker, than anti-
-TPO, who developed hypothyroidism. Thus, anti-TG
seems to be of less usefulnesss in predicting thyroid
dysfunction42. Still, thyroid antibodies can predict thy-
roid dysfunction in children suffering from T1D with
sensitivity of 50% and with specificity of 84%28. Accord-
ing to Gonzales anti-TG showed less sensitivity than
anti-TPO. The latter antibodies can predict thyroid dys-
function with 95% of sensitivity and with 96% of spe-
cificity30. There are rare reports suggesting an equal sen-
sitivity of both thyroid antibodies9.
The results in the present study showed that there
were no significant differences in thyroid dysfunction be-
tween the groups of patients with mild (100–1000 IU/
mL) and high (>1000 IU/mL) serum elevation of thyroid
antibodies. However, there are some reports suggesting
that a mild serum elevation of thyroid antibodies does
not lead to hypothyroidism as it happened in 75% of pa-
tients with high serum levels of thyroid antibodies43.
Thus, there seems to exist a certain degree of correlation
between high serum levels of thyroid antibodies and de-
velopment of hypothyroidism5.
The presented results showed that ultrasonographic
findings of thyroid gland were not normal in almost all
our patients with AIT. But, there were any significant
differences in thyroid ultrasonography between AIT sub-
jects with and without thyroid dysfunction. According to
literature data only 10% of children with mild, and even
83% of children with high serum levels of thyroid anti-
bodies had developed ultrasonographic signs typical for
AIT43. Kordonouri reported that 87.5% of patients with
AIT, and all the patients with AITD showed certain
ultrasonographic changes of thyroid gland5,9.
Comparisons of weight, BMI, insulin dose, HbA1c and
the number of severe hypoglycemic episodes between di-
abetic patients with and without AIT did not present
with significant differences in the present and in many
other similar studies4,16,17,29,33,. We assume that possible
complications were prevented because of frequently per-
formed AIT screening that resulted in early recognition
of the disease. Nevertheless, some studies have showed
that patients with hypothyroidism had significantly
more symptomatic hypoglycaemic episodes during the 12
months before diagnosis, incresing progressively during
thise time period and reaching a peak at the moment of
diagnosis19. Moreover, it has been suggested that recur-
rent hypoglycaemia is a presenting sign of underlaying
hypothyroidism44. The consensus guidelines 2000 of
ISPAD (International Society for Paediatric and Adoles-
cent Diabetes) suggest that hypothyroidsm might influ-
ence metabolic control45. It seems that growth potential
among people with Type 1 diabetes and subclinical hy-
pothyroidsm may be significantly reduced20.
Conclusion
The results of the present study confirmed frequent
occurrence of AIT and AITD in children and adolesents
suffering from T1D. The number of newly diagnosed pa-
tients with AIT reached the peak at the age of puberty.
Girls were significantly more predisposed to AIT at any
age. Among the patients with serum elevated thyroid an-
tibodies AITD showed to be significantly more frequent
in boys. There was no relation between the rate of thy-
roid antibodies serum elevation and thyroid dysfunction,
as there were no differences in growth and metabolic
control between patients with and without AIT. Annual
screening of thyroid antibodies, particularly anti-TPO, in
all children and adolescents with T1D is recommended.
The serum TSH level should be measured in all patients
with serum elevated thyroid antibodies.
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EPIDEMIOLOGIJA I KLINI^KA OBILJE@JA PORME]AJA RADA [TITNJA^E U DJECE I
ADOLESCENATA OBOLJELIH OD [E]ERNE BOLESTI TIPA 1
S A @ E T A K
Cilj rada je utvrditi tijek autoimunog tireoiditisa (AIT) i autoimune bolesti {titnja~e (AITD) u djece i adolescentaa
oboljelih od tip 1 {e}erne bolesti (T1D) te ~imbenike rizika za njihov razvoj. Tako|er, analizirani su utjecaj AIT na rast,
razvoj i metaboli~ku kontrolu dijabeti~ara. Istra`ivanje je obuhvatilo 148 djece i adolescenata s T1D, 50,7% mu{kih (dob
1–21 g.) Od 1995. g., tijekom 12 godi{njeg razdoblja, jednom godi{nje je u~injen probir na AIT mjerenjem koncentracije
antitireoglobulinskih (anti-TG) i antitireoperoksidaznih antitijela (anti-TPO) i funkciju {titnja~e mjerenjem tireotrop-
nog hormona (TSH) i tiroksina (T4). Srednje vrijeme pra}enja je bilo 7 ± 4,1 g. Na tromjese}nim kontrolama pacijenti-
ma se mjerila visina, masa i indeks tjelesne mase (BMI), bilje`ila se inzulinska doza, broj te{kih hipoglikemija te se
odre|ivao glikolizirani hemoglobin (HbA1c). Prevalencija AIT u djece i adolescenata oboljelih od T1D je 15,5% i ~e{}i je
kod `enskih ispitanika, 21,9%:9,3% (p=0,03). Srednja dob javljanja AIT je 11,5 ± 5,2 g. Srednja dob intervala izme|u
negativnog i pozitivnog probira je 2,5 ± 2,3 g. Nakon 6 g. trajanja T1D kumulativna incidencija AIT je zna~ajno vi{a u
djevoj~ica (30%:15%) (p=0,0254). Prevalencija hipotireoze je 8,1% u svih pacijenata s T1D, nema zna~ajne razlike me|u
spolovima. Prevalencija hipotireoze je 52,2% u ispitanika sa pozitivnim antitireoidnim antitijelima. Niti jedan pacijent
nije razvio hipotireozu ukoliko nije imao pozitivna antitireoidna antitijela. U bolesnika s pozitivnim antitireoidnim
antitijelima hipotireoza je signifikantno vi{a u mu{kih 85,7%:37,5% (p=0,0052). Kumulativna incidencija hipotireoze u
oboljelih od T1D nakon 3 g. od pojave povi{enih antitireoidnih antitijela je 55% i zna~ajno je ~e{}a u dje~aka nego u
djevoj~ica 85%:40% (p=0,0052). Od po~etka T1D do razvoja hipotireoze srednje vrijeme je 3,3 ± 2,5 g. Od pojave pozi-
tivnih antitireoidnih antitijela do razvoja hipotireoze srednje vrijeme je 1,7 ± 1,2 g. Srednja dob nastanka hipotireoze je
12,7 ± 5,3 g. Visina, BMI, inzulinska doza, HbA1c i u~estalost te{kih hipoglikemija nisu se zna~ajno razlikovali izme|u
skupine sa T1D bez i sa AIT. Utvr|ena je visoka pojavnost AIT i AITD u djece i adolescenata sa T1D. AIT se zna~ajno
~e{}e javlja u djevoj~ica u svakoj dobi. Me|u pacijentima sa povi{enim antitireodnim antitijelaima, AITD je signifi-
kantno ~e{}a u dje~aka. Nema razlike u rastu, razvoju i kontroli glikemije u pacijenta sa i bez AIT. Na{i rezultati
sugeriraju godi{nji probir u sve djece i adolescenata sa T1D na antitireoidna antitijela, naro~ito anti-TPO, a ispitivanje
TSH u onih sa povi{enim antitroidnim antitijelima.
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